152 related articles for article (PubMed ID: 37961351)
1. ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers.
Xu Y; Wang Z; Sjöström M; Deng S; Wang C; Johnson NA; Gonzalez J; Li X; Metang LA; Tirado CR; Mukherji A; Wainwright G; Yu X; Yang Y; Barnes S; Hofstad M; Zhu H; Hanker A; He HH; Chen Y; Wang Z; Raj G; Arteaga C; Feng F; Wang Y; Wang T; Mu P
bioRxiv; 2023 Oct; ():. PubMed ID: 37961351
[TBL] [Abstract][Full Text] [Related]
2. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
[TBL] [Abstract][Full Text] [Related]
3. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.
Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY
Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903
[TBL] [Abstract][Full Text] [Related]
4. Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance.
Deng S; Wang C; Wang Y; Xu Y; Li X; Johnson NA; Mukherji A; Lo UG; Xu L; Gonzalez J; Metang LA; Ye J; Tirado CR; Rodarte K; Zhou Y; Xie Z; Arana C; Annamalai V; Liu X; Vander Griend DJ; Strand D; Hsieh JT; Li B; Raj G; Wang T; Mu P
Nat Cancer; 2022 Sep; 3(9):1071-1087. PubMed ID: 36065066
[TBL] [Abstract][Full Text] [Related]
5. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
Kim DH; Sun D; Storck WK; Welker Leng K; Jenkins C; Coleman DJ; Sampson D; Guan X; Kumaraswamy A; Rodansky ES; Urrutia JA; Schwartzman JA; Zhang C; Beltran H; Labrecque MP; Morrissey C; Lucas JM; Coleman IM; Nelson PS; Corey E; Handelman SK; Sexton JZ; Aggarwal R; Abida W; Feng FY; Small EJ; Spratt DE; Bankhead A; Rao A; Gesner EM; Attwell S; Lakhotia S; Campeau E; Yates JA; Xia Z; Alumkal JJ
Clin Cancer Res; 2021 Sep; 27(17):4923-4936. PubMed ID: 34145028
[TBL] [Abstract][Full Text] [Related]
6. Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer.
Cheng WC; Wang HJ
Tzu Chi Med J; 2021; 33(3):224-232. PubMed ID: 34386358
[TBL] [Abstract][Full Text] [Related]
7. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.
Beltran H; Hruszkewycz A; Scher HI; Hildesheim J; Isaacs J; Yu EY; Kelly K; Lin D; Dicker A; Arnold J; Hecht T; Wicha M; Sears R; Rowley D; White R; Gulley JL; Lee J; Diaz Meco M; Small EJ; Shen M; Knudsen K; Goodrich DW; Lotan T; Zoubeidi A; Sawyers CL; Rudin CM; Loda M; Thompson T; Rubin MA; Tawab-Amiri A; Dahut W; Nelson PS
Clin Cancer Res; 2019 Dec; 25(23):6916-6924. PubMed ID: 31363002
[TBL] [Abstract][Full Text] [Related]
8. ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer.
Tabrizian N; Nouruzi S; Cui CJ; Kobelev M; Namekawa T; Lodhia I; Talal A; Sivak O; Ganguli D; Zoubeidi A
Cell Rep; 2023 Aug; 42(8):112937. PubMed ID: 37552603
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC).
Xu H; Liu Z; Gao D; Li P; Shen Y; Sun Y; Xu L; Song N; Wang Y; Zhan M; Gao X; Wang Z
Mol Metab; 2022 May; 59():101466. PubMed ID: 35219875
[TBL] [Abstract][Full Text] [Related]
10. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
Berger A; Brady NJ; Bareja R; Robinson B; Conteduca V; Augello MA; Puca L; Ahmed A; Dardenne E; Lu X; Hwang I; Bagadion AM; Sboner A; Elemento O; Paik J; Yu J; Barbieri CE; Dephoure N; Beltran H; Rickman DS
J Clin Invest; 2019 Jul; 129(9):3924-3940. PubMed ID: 31260412
[TBL] [Abstract][Full Text] [Related]
11. The epigenetic and transcriptional landscape of neuroendocrine prostate cancer.
Davies A; Zoubeidi A; Selth LA
Endocr Relat Cancer; 2020 Feb; 27(2):R35-R50. PubMed ID: 31804971
[TBL] [Abstract][Full Text] [Related]
12. Lineage plasticity-mediated therapy resistance in prostate cancer.
Blee AM; Huang H
Asian J Androl; 2019; 21(3):241-248. PubMed ID: 29900883
[TBL] [Abstract][Full Text] [Related]
13. Targeting Nr2e3 to Modulate Tet2 Expression: Therapeutic Potential for Depression Treatment.
Ma X; Xu S; Zhou Y; Zhang Q; Yang H; Wan B; Yang Y; Miao Z; Xu X
Adv Sci (Weinh); 2024 Jun; ():e2400726. PubMed ID: 38881534
[TBL] [Abstract][Full Text] [Related]
14. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.
Davies A; Nouruzi S; Ganguli D; Namekawa T; Thaper D; Linder S; Karaoğlanoğlu F; Omur ME; Kim S; Kobelev M; Kumar S; Sivak O; Bostock C; Bishop J; Hoogstraat M; Talal A; Stelloo S; van der Poel H; Bergman AM; Ahmed M; Fazli L; Huang H; Tilley W; Goodrich D; Feng FY; Gleave M; He HH; Hach F; Zwart W; Beltran H; Selth L; Zoubeidi A
Nat Cell Biol; 2021 Sep; 23(9):1023-1034. PubMed ID: 34489572
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract][Full Text] [Related]
16. Wntless expression promotes lineage plasticity and is associated with neuroendocrine prostate cancer.
D'Abronzo LS; Lombard AP; Ning S; Armstong CM; Leslie AR; Sharifi M; Schaaf ZA; Lou W; Gao AC
Am J Clin Exp Urol; 2022; 10(5):299-310. PubMed ID: 36313205
[TBL] [Abstract][Full Text] [Related]
17. ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.
Jing N; Zhang K; Chen X; Liu K; Wang J; Xiao L; Zhang W; Ma P; Xu P; Cheng C; Wang D; Zhao H; He Y; Ji Z; Xin Z; Sun Y; Zhang Y; Bao W; Gong Y; Fan L; Ji Y; Zhuang G; Wang Q; Dong B; Zhang P; Xue W; Gao WQ; Zhu HH
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 38099497
[TBL] [Abstract][Full Text] [Related]
18.
Blee AM; He Y; Yang Y; Ye Z; Yan Y; Pan Y; Ma T; Dugdale J; Kuehn E; Kohli M; Jimenez R; Chen Y; Xu W; Wang L; Huang H
Clin Cancer Res; 2018 Sep; 24(18):4551-4565. PubMed ID: 29844131
[No Abstract] [Full Text] [Related]
19. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
Tang DE; Dai Y; He JX; Lin LW; Leng QX; Geng XY; Fu DX; Jiang HW; Xu SH
J Pathol; 2020 Oct; 252(2):101-113. PubMed ID: 32617978
[TBL] [Abstract][Full Text] [Related]
20. The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity.
Davies A; Zoubeidi A; Beltran H; Selth LA
Cancer Discov; 2023 Aug; 13(8):1771-1788. PubMed ID: 37470668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]